These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 34987657

  • 1. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z, Zhang X, Khong PL, Chen X.
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [Abstract] [Full Text] [Related]

  • 2. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z.
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [Abstract] [Full Text] [Related]

  • 3. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y, Zhao L, Fang J, Chen J, Meng L, Sun L, Wu H, Guo Z, Lin Q, Chen H.
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [Abstract] [Full Text] [Related]

  • 4. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy.
    Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, Liu Z.
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1985-1996. PubMed ID: 34746969
    [Abstract] [Full Text] [Related]

  • 5. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T, Peng L, Qiu J, He X, Zhang D, Wu R, Liu J, Zhang X, Zha Z.
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [Abstract] [Full Text] [Related]

  • 6. Preparation and Bioevaluation of 99mTc-Labeled FAP Inhibitors as Tumor Radiotracers to Target the Fibroblast Activation Protein.
    Ruan Q, Feng J, Jiang Y, Zhang X, Duan X, Wang Q, Yin G, Xiao D, Zhang J.
    Mol Pharm; 2022 Jan 03; 19(1):160-171. PubMed ID: 34904839
    [Abstract] [Full Text] [Related]

  • 7. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression.
    Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X.
    Eur J Nucl Med Mol Imaging; 2023 Jul 03; 50(9):2846-2860. PubMed ID: 37097443
    [Abstract] [Full Text] [Related]

  • 8. Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.
    Millul J, Koepke L, Haridas GR, Sparrer KMJ, Mansi R, Fani M.
    Eur J Nucl Med Mol Imaging; 2023 Aug 03; 50(10):3050-3061. PubMed ID: 37261473
    [Abstract] [Full Text] [Related]

  • 9. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
    Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marmé F, Jäger D, Mier W, Haberkorn U.
    J Nucl Med; 2019 Oct 03; 60(10):1421-1429. PubMed ID: 30850501
    [Abstract] [Full Text] [Related]

  • 10. 18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention.
    Li H, Ye S, Li Li, Zhong J, Yan Q, Zhong Y, Feng P, Hu K.
    Eur J Nucl Med Mol Imaging; 2022 Jul 03; 49(8):2705-2715. PubMed ID: 35290473
    [Abstract] [Full Text] [Related]

  • 11. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor.
    Toms J, Kogler J, Maschauer S, Daniel C, Schmidkonz C, Kuwert T, Prante O.
    J Nucl Med; 2020 Dec 03; 61(12):1806-1813. PubMed ID: 32332144
    [Abstract] [Full Text] [Related]

  • 12. Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2.
    Läppchen T, Bilinska A, Pilatis E, Menéndez E, Imlimthan S, Moon ES, Afshar-Oromieh A, Rösch F, Rominger A, Gourni E.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999044
    [Abstract] [Full Text] [Related]

  • 13. Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy.
    Lindner T, Altmann A, Krämer S, Kleist C, Loktev A, Kratochwil C, Giesel F, Mier W, Marme F, Debus J, Haberkorn U.
    J Nucl Med; 2020 Oct 28; 61(10):1507-1513. PubMed ID: 32169911
    [Abstract] [Full Text] [Related]

  • 14. Development and Evaluation of DOTA-FAPI-Maleimide as a Novel Radiotracer for Tumor Theranostic with Extended Circulation.
    Feng L, Hu W, Zeng X, Wei Z, Long Y, Li M, Sun S, Guo Z, Lan X, Zhang X, Zhuang R, Jiang D.
    Mol Pharm; 2024 Sep 02; 21(9):4386-4394. PubMed ID: 39046432
    [Abstract] [Full Text] [Related]

  • 15. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L, Chen J, Pang Y, Fang J, Fu K, Meng L, Zhang X, Guo Z, Wu H, Sun L, Su G, Lin Q, Chen H.
    Mol Pharm; 2022 Oct 03; 19(10):3640-3651. PubMed ID: 35917335
    [Abstract] [Full Text] [Related]

  • 16. Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013.
    Tan Y, Li J, Zhao T, Zhou M, Liu K, Xiang S, Tang Y, Jakobsson V, Xu P, Chen X, Zhang J.
    Eur J Nucl Med Mol Imaging; 2024 Jul 03; 51(9):2761-2773. PubMed ID: 38561515
    [Abstract] [Full Text] [Related]

  • 17. Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
    Galbiati A, Bocci M, Ravazza D, Mock J, Gilardoni E, Neri D, Cazzamalli S.
    J Nucl Med; 2024 Oct 01; 65(10):1604-1610. PubMed ID: 39266289
    [Abstract] [Full Text] [Related]

  • 18. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, Windisch P, Hielscher T, Flechsig P, Floca R, Leitz D, Schuster JP, Huber PE, Debus J, von Deimling A, Lindner T, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2019 Nov 01; 46(12):2569-2580. PubMed ID: 31388723
    [Abstract] [Full Text] [Related]

  • 19. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models.
    Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, Toyoshima A, Nagata K, Shimosegawa E, Haberkorn U, Kratochwil C, Shinohara A, Giesel F, Hatazawa J.
    J Nucl Med; 2020 Apr 01; 61(4):563-569. PubMed ID: 31586001
    [Abstract] [Full Text] [Related]

  • 20. 68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention.
    Huang J, Zhang X, Liu Q, Gong F, Huang Y, Huang S, Fu L, Tang G.
    J Med Chem; 2024 Oct 10; 67(19):17785-17795. PubMed ID: 39321030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.